Adjuvant docetaxel without prednisone failed to improve biochemical disease-free survival in men with intermediate- or high-risk prostate cancer who have undergone radical radiotherapy with androgen deprivation therapy, according to results of the Scandinavian Prostate Cancer Group’s multinational phase III SPCG-13 trial.
Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
source: Cancer Network